Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer

Breast Cancer Res. 2020 May 20;22(1):52. doi: 10.1186/s13058-020-01294-7.

Lori J Goldstein¹, Raymond P Perez^{2

3}, Denise Yardley^{4

5}, Linda K Han^{6

7}, James M Reuben⁸, Hui Gao⁸, Susan McCanna⁹, Beth Butler⁹, Pier Adelchi Ruffini⁹, Yi Liu¹⁰, Roberto R Rosato¹⁰, Jenny C Chang¹¹

¹ Department of Medical Oncology, The Hospital of Fox Chase Cancer Center, Philadelphia, PA, USA.
² University of Kansas Medical Research Center, Fairway, KS, USA.
³ Current address: Early Oncology Development, Bristol-Myers Squibb, 3401 Princeton Pike, Lawrenceville, NJ, 08648, USA.
⁴ Tennessee Oncology, Nashville, TN, USA.
⁵ Sarah Cannon Research Institute, 250 25th Avenue North Suite 200, Nashville, TN, 37203, USA.
⁶ Indiana University Simon Cancer Center, Indianapolis, IN, USA.
⁷ Current address: Parkview Cancer Institute, 11141 Parkview Plaza, Suite 305A, Fort Wayne, IN, 46845, USA.
⁸ Department of Hematopathology-Research, MD Anderson Cancer Center, Houston, TX, USA.
⁹ Research and Development, Dompé farmaceutici S.p.A., 20122, Milan, Italy.
¹⁰ The Methodist Hospital Research Institute, 6445 Main Street, Houston, TX, 77030, USA.
¹¹ The Methodist Hospital Research Institute, 6445 Main Street, Houston, TX, 77030, USA. jcchang@houstonmethodist.org.

Abstract

An amendment to this paper has been published and can be accessed via the original article.